Patients with colorectal cancer starting adjuvant or first-line treatment with a chemotherapy combination containing fluorouracil , capecitabine , and/or irinotecan were randomly assigned to receive octreotide LAR 30 mg intramuscularly every 4 weeks ( experimental arm ) or the physician 's treatment of choice in case of diarrhea ( control arm ) .